The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Anti-obesity drugs: past, present and future
Open accessAbstract
The ideal anti-obesity drug would produce sustained weight loss with minimal side effects. The mechanisms that regulate energy balance have substantial built-in redundancy, overlap considerably with other physiological functions, and are influenced by social, hedonic and psychological factors that limit the effectiveness of pharmacological interventions. It is therefore unsurprising that anti-obesity drug discovery programmes have been littered with false starts, failures in clinical development, and withdrawals due to adverse effects that were not fully appreciated at the time of launch. Drugs that target pathways in metabolic tissues, such as adipocytes, liver and skeletal muscle, have shown potential in preclinical studies but none has yet reached clinical development. Recent improvements in the understanding of peptidergic signalling of hunger and satiety from the gastrointestinal tract mediated by ghrelin, cholecystokinin (CCK), peptide YY (PYY) and glucagon-like peptide-1 (GLP-1), and of homeostatic mechanisms related to leptin and its upstream pathways in the hypothalamus, have opened up new possibilities. Although some have now reached clinical development, it is uncertain whether they will meet the strict regulatory hurdles required for licensing of an anti-obesity drug. However, GLP-1 receptor agonists have already succeeded in diabetes treatment and, owing to their attractive body-weight-lowering effects in humans, will perhaps also pave the way for other anti-obesity agents. To succeed in developing drugs that control body weight to the extent seen following surgical intervention, it seems obvious that a new paradigm is needed. In other therapeutic arenas, such as diabetes and hypertension, lower doses of multiple agents targeting different pathways often yield better results than strategies that modify one pathway alone. Some combination approaches using peptides and small molecules have now reached clinical trials, although recent regulatory experience suggests that large challenges lie ahead. In future, this polytherapeutic strategy could possibly rival surgery in terms of efficacy, safety and sustainability of weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
‘Small Changes' to Diet and Physical Activity Behaviors for Weight Management
Hills, A. P., Byrne, N. M., Lindstrom, R., & Hill, J. O. (2013) · Obesity Facts · doi:10.1159/000345030 · Cited by 9,493
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Kopelman, P. G. (2000) · Nature · doi:10.1038/35007508 · Cited by 4,795
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668 · cited 1×
“Bariatric surgery, such as Roux-en-Y bypass or gastric banding, is much more effective in terms of weight loss, comorbidity reduction and enhanced survival (Kral and Naslund, 2007; Sjostrom et al., 2007).”
BackgroundHaslam, D. W., & James, W. P. T. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67483-1 · Cited by 3,757
Years of Life Lost Due to Obesity
Fontaine, K. R., Redden, D. T., Wang, C., Westfall, A. O., & Allison, D. B. (2003) · JAMA · doi:10.1001/jama.289.2.187 · Cited by 2,495
Fuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Self-citationGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915 · cited 2×
“, 2005)], but of sufficient magnitude to have beneficial effects on cardiovascular risk, as reflected by a lowering of low-density-lipoprotein (LDL) cholesterol, blood pressure and glycaemia (Broom et al., 2002; Torgerson et al., 2004).”
Background
Cited by
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
Self-citationEmdin, C. A., Khera, A. V., Natarajan, P., Klarin, D., Zekavat, S. M., Hsiao, A. J., & Kathiresan, S. (2017) · JAMA · doi:10.1001/jama.2016.21042 · Cited by 378
Serotonin controlling feeding and satiety
Voigt, J.-P., & Fink, H. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.08.065 · Cited by 312
Zaykov, A. N., Mayer, J. P., & DiMarchi, R. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.36 · Cited by 287
Adipokines – removing road blocks to obesity and diabetes therapy
Blüher, M. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.01.005 · Cited by 273
Antiobesity carbonic anhydrase inhibitors: a literature and patent review
Scozzafava, A., Supuran, C. T., & Carta, F. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.790957 · Cited by 273
Altered gut and adipose tissue hormones in overweight and obese individuals: Cause or consequence?
Lean, M. E. J., & Malkova, D. (2016) · International Journal of Obesity · doi:10.1038/ijo.2015.220 · Cited by 253
Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
Van Gaal, L., & Scheen, A. (2015) · Diabetes Care · doi:10.2337/dc14-1630 · Cited by 221
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
Self-citationOnakpoya, I. J., Heneghan, C. J., & Aronson, J. K. (2016) · BMC Medicine · doi:10.1186/s12916-016-0735-y · Cited by 171
O'Neil, P. M., Aroda, V. R., Astrup, A., Kushner, R., Lau, D. C. W., Wadden, T. A., Brett, J., Cancino, A., Wilding, J. P. H., & groups, O. B. O. T. S. A. C. A. –. L. E. I. I. W. A. W. D. (. S. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12963 · Cited by 115
Self-citationDrug treatment of obesity: Current status and future prospects
Kakkar, A. K., & Dahiya, N. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.01.005 · Cited by 113
Clemmensen, C., Finan, B., Fischer, K., Tom, R. Z., Legutko, B., Sehrer, L., Heine, D., Grassl, N., Meyer, C. W., Henderson, B., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404508 · Cited by 89
Self-citationCardiovascular outcome trials in obesity: A review
Wilding, J. P. H., & Jacob, S. (2021) · Obesity Reviews · doi:10.1111/obr.13112 · Cited by 75
“Anti-obesity drugs are constantly monitored for any potential safety issues that would necessitate drug withdrawals.(42,43)”
BackgroundSelf-citationThe Role of Momordica charantia in Resisting Obesity
Fan, M., Kim, E.-K., Choi, Y.-J., Tang, Y., & Moon, S.-H. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16183251 · Cited by 65
Fu, Y.-Y., Zhang, M., Turner, N., Zhang, L.-N., Dong, T.-C., Gu, M., Leslie, S. J., Li, J.-Y., Nan, F.-J., & Li, J. (2013) · Diabetologia · doi:10.1007/s00125-013-2987-9 · Cited by 35
The Societal Value of Broader Access to Antiobesity Medications
Kabiri, M., Sexton Ward, A., Ramasamy, A., van Eijndhoven, E., Ganguly, R., Smolarz, B. G., Zvenyach, T., Goldman, D. P., & Baumgardner, J. R. (2020) · Obesity · doi:10.1002/oby.22696 · Cited by 26
Alsuhibani, A., Alrasheed, M., Gari, M., Hincapie, A. L., & Guo, J. J. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-021-01330-2 · Cited by 19
Obesity in Yap transgenic mice is associated with TAZ downregulation
Kamura, K., Shin, J., Kiyonari, H., Abe, T., Shioi, G., Fukuhara, A., & Sasaki, H. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.10.037 · Cited by 16
Anti-Adipogenic Activity of Rhaponticum carthamoides and Its Secondary Metabolites
Todorova, V., Savova, M. S., Ivanova, S., Ivanov, K., & Georgiev, M. I. (2023) · Nutrients · doi:10.3390/nu15133061 · Cited by 12
Fortin, S. M., Chen, J., & Hayes, M. R. (2020) · Physiology & Behavior · doi:10.1016/j.physbeh.2020.112870 · Cited by 10
Metadata
- Authors
- Rodgers, R. J., Tschöp, M. H., & Wilding, J. P. H.
- Venue
- Disease Models & Mechanisms
- Publisher
- The Company of Biologists
- Published
- 2012-09-01
- Volume
- 5
- Issue
- 5
- Pages
- 621-626
- ISSN
- 1754-8403 (ISSN-L)
- 1754-8411
- OpenAlex
- W2160235960
- Cited by
- 430
- References
- 73
- FWCI
- 21.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.